Cisplatin in Chemotherapy

Mehmet Erdem; Mehmet Özaslan

doi:10.55549/zbs.1581366

EN

Cisplatin in Chemotherapy

Abstract

Chemotherapy is a cancer treatment used to halt the uncontrolled growth of cancer cells. Despite the increase in cancer survival rates due to aggressive treatments, new anticancer drugs often cause severe side effects that can last for years, sometimes leading to treatment discontinuation or dose reduction. Chemotherapy-induced peripheral neuropathy is the most dose-limiting side effect of anticancer agents like paclitaxel, vincristine, and platinum compounds commonly used in treating various tumors. Many of these drugs impact the nervous system, with neurotoxicity being one of the most significant side effects. Cisplatin, a platinum-based compound widely used in cancer treatment, exerts its effect by binding to purine residues in DNA, chelating and leading to apoptosis in cancer cells. This mechanism enables it to be used as an antineoplastic agent in treating various solid tumors, including testicular, ovarian, bladder, head-and-neck, and lung cancers. One of the most serious issues associated with cisplatin chemotherapy is neurotoxicity, with oxidative stress being a major factor. Other mechanisms contributing to cisplatin neurotoxicity include DNA-mediated apoptotic pathways, mitochondrial damage, activation of pro-inflammatory cytokines, ion channel disruptions, and glial activation. Research aimed at reducing cisplatin’s neurotoxicity risk holds promise for making cisplatin a safer and more effective treatment option in the future.

Keywords

Chemotherapy, cisplatin, neurotoxicity

References

Abdel-Wahab, W. M., & Moussa, F. I. (2019). Neuroprotective effect of N-acetylcysteine against sisplatin-induced toxicity in rat brain by modulation of oxidative stress and inflammation. Drug design, development and therapy, 1155-1162.
Almutairi, M. M., Alanazi, W. A., Alshammari, M. A., Alotaibi, M. R., Alhoshani, A. R., Al-Rejaie, S. S., ... & Al-Shabanah, O. A. (2017). Neuro-protective effect of rutin against Sisplatin-induced neurotoxic rat model. BMC complementary and alternative medicine, 17, 1-9.
Arafa, M. H., & Atteia, H. H. (2020). Protective role of epigallocatechin gallate in a rat model of sisplatin-induced cerebral inflammation and oxidative damage: Impact of modulating NF-κB and Nrf2. Neurotoxicity Research, 37(2), 380-396.
Areti, A., Yerra, V. G., Naidu, V. G. M., & Kumar, A. (2014). Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy. Redox biology, 2, 289-295.
Arrieta, O., García‐Navarrete, R., Zuniga, S., Ordóñez, G., Ortiz, A., Palencia, G., ... & Sotelo, J. (2005). Retinoic acid increases tissue and plasma contents of nerve growth factor and prevents neuropathy in diabetic mice. European journal of clinical investigation, 35(3), 201-207.
Argyriou, A. A., Chroni, E., Polychronopoulos, P., Iconomou, G., Koutras, A., Makatsoris, T., ... & Kalofonos, H. P. (2006). Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology, 67(12), 2253-2255.
Argyriou, A. A., Cavaletti, G., Briani, C., Velasco, R., Bruna, J., Campagnolo, M., ... & Kalofonos, H. P. (2013). Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer, 119(2), 438-444
Astolfi, L., Ghiselli, S., Guaran, V., Chicca, M., Simoni, E. D. I., Olivetto, E., ... & Martini, A. (2013). Correlation of adverse effects of sisplatin administration in patients affected by solid tumours: A retrospective evaluation. Oncology reports, 29(4), 1285-1292.
Barhwal, K., Hota, S. K., Prasad, D., Singh, S. B., & Ilavazhagan, G. (2008). Hypoxia‐induced deactivation of NGF‐mediated ERK1/2 signaling in hippocampal cells: Neuroprotection by acetyl‐L‐carnitine. Journal of neuroscience research, 86(12), 2705-2721.
Bennett, G. J., Liu, G. K., Xiao, W. H., Jin, H. W., & Siau, C. (2011). Terminal arbor degeneration--a novel lesion produced by the antineoplastic agent paclitaxel. Eur J Neurosci, 33(9), 1667-1676. doi:10.1111/j.1460- 9568.2011.07652.x

Bobylev, I., Joshi, A. R., Barham, M., Neiss, W. F., & Lehmann, H. C. (2018). Depletion of mitofusin-2 causes mitochondrial damage in sisplatin-induced neuropathy. Molecular neurobiology, 55, 1227-1235.
Boehmerle, W., Huehnchen, P., Peruzzaro, S., Balkaya, M., & Endres, M. (2014). Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice. Scientific reports, 4(1), 6370.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424.
Brouwers, E. E., Huitema, A. D., Boogerd, W., Beijnen, J. H., & Schellens, J. H. (2009). Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncologica, 48(6), 832-841.
Calls, A., Torres-Espin, A., Navarro, X., Yuste, V. J., Udina, E., & Bruna, J. (2021). Cisplatin-induced peripheral neuropathy is associated with neuronal senescence-like response. Neuro-oncology, 23(1), 88-99.
Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M.,. . . Catalano, G. (2002). Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol, 20(16), 3478-3483. doi:10.1200/jco.2002.07.061
Cascinu, S., Cordella, L., Del Ferro, E., Fronzoni, M., & Catalano, G. (1995). Neuroprotective effect of reduced glutathione on sisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. Journal of Clinical Oncology, 13(1), 26-32.
Cassidy, J., Paul, J., Soukop, M., Habeshaw, T., Reed, N. S., Parkin, D., & Kaye, S. B. (1997). Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with sisplatin. Cancer chemotherapy and pharmacology, 41, 161-166.
Cavaletti, G., Alberti, P., & Marmiroli, P. (2011). Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. The lancet oncology, 12(12), 1151-1161.
Cavaletti, G., Minoia, C., Schieppati, M., & Tredici, G. (1994). Protective effects of glutathione on sisplatin neurotoxicity in rats. International Journal of Radiation Oncology* Biology* Physics, 29(4), 771-776.
Cavaletti, G., Tredici, G., Marmiroli, P., Petruccioli, M. G., Barajon, I., & Fabbrica, D. (1992). Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic sisplatin (DDP) administration in rats. Acta Neuropathol, 84(4), 364-371. doi:10.1007/bf00227662
Cepeda, V., Fuertes, M. A., Castilla, J., Alonso, C., Quevedo, C., & Pérez, J. M. (2007). Biochemical mechanisms of cisplatin cytotoxicity. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 7(1), 3-18.
Chiu, G. S., Maj, M. A., Rizvi, S., Dantzer, R., Vichaya, E. G., Laumet, G., ... & Heijnen, C. J. (2017). Pifithrin-μ prevents sisplatin-induced chemobrain by preserving neuronal mitochondrial function. Cancer research, 77(3), 742-752.
Choi, Y. M., Kim, H. K., Shim, W., Anwar, M. A., Kwon, J. W., Kwon, H. K., ... & Choi, S. (2015). Mechanism of sisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation. PloS one, 10(8), e0135083.
Chovanec, M., Zaid, M. A., Hanna, N., El-Kouri, N., Einhorn, L. H., & Albany, C. (2017). Long-term toxicity of sisplatin in germ-cell tumor survivors. Annals of Oncology, 28(11), 2670-2679.
Chtourou, Y., Gargouri, B., Kebieche, M., & Fetoui, H. (2015). Naringin abrogates sisplatin-induced cognitive deficits and cholinergic dysfunction through the down-regulation of AChE expression and iNOS signaling pathways in hippocampus of aged rats. Journal of Molecular Neuroscience, 56, 349-362.
Colombo, N., Bini, S., Miceli, D., Bogliun, G., Marzorati, L., Cavaletti, G., ... & Mangioni, C. (1995). Weekly sisplatin±glutathione in relapsed ovarian carcinoma. International Journal of Gynecologic Cancer, 5(2).
Dasari, S., & Tchounwou, P. B. (2014). Sisplatin in cancer therapy: molecular mechanisms of action. European journal of pharmacology, 740, 364-378.
de Castro Jr, G., Alves, G. V., Castro, A. F., Chaves, A. L., De Marchi, P., de Oliveira, T. B., ... & Mora, P. A. (2018). Criteria for eligibility to sisplatin in the curative treatment of head and neck cancer: consensus opinion from a panel of experts. Critical Reviews in Oncology/Hematology, 131, 30-34.
Decatris, M. P., Sundar, S., & O’byrne, K. J. (2004). Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer treatment reviews, 30(1), 53-81.
DeConti, R., Toftness, B., Lange, R., Creasey W., (1973). Clinical and pharmacological studies with cis‐Diamminedichloro platinum (II). Cancer Res, 33:1310‐1315.
Eljack, N. D., Ma, H. Y., Drucker, J., Shen, C., Hambley, T. W., New, E. J., . . . Clarke, R. J. (2014). Mechanisms of cell uptake and toxicity of the anticancer drug sisplatin. Metallomics, 6(11), 2126-2133. doi:10.1039/c4mt00238e
Fumagalli, G., Monza, L., Cavaletti, G., Rigolio, R., & Meregalli, C. (2021). Neuroinflammatory process involved in different preclinical models of chemotherapy-induced peripheral neuropathy. Frontiers in immunology, 11, 626687.
Gallardo, Mohar, Calderillo, Mota, Solorza, Lozano, ... & La Garza, D. (1999). Sisplatin, radiation, and amifostine in carcinoma of the uterine cervix. International Journal of Gynecological Cancer, 9(3), 225-230.
Gamelin, L., Boisdron-Celle, M., Delva, R., Guerin-Meyer, V., Ifrah, N., Morel, A., & Gamelin, E. (2004). Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res, 10(12 Pt 1), 4055-4061. doi:10.1158/1078-0432.Ccr-03-0666
Gandara, D. R., Nahhas, W. A., Adelson, M. D., Lichtman, S. M., Podczaski, E. S., Yanovich, S., ... & Weisberg, S. R. (1995). Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. Journal of clinical oncology, 13(2), 490-496.
Guo, C., Sun, L., Chen, X., & Zhang, D. (2013). Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural regeneration research, 8(21), 2003-2014.
Guo, Y., Jones, D., Palmer, J. L., Forman, A., Dakhil, S. R., Velasco, M. R., ... & Fisch, M. J. (2014). Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Supportive care in cancer, 22, 1223-1231.
Han, Y., & Smith, M. T. (2013). Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Frontiers in pharmacology, 4, 156.
Hashem, R. M., Safwar, G. M., Rashed, L. A., & Bakry, S. (2015). Biochemical findings on cisplatin-induced oxidative neurotoxicity in rats. International journal of Advanced Research, 3, 1222-1234.
Hess, L. M., Benham-Hutchins, M., Herzog, T. J., Hsu, C. H., Malone, D. C., Skrepnek, G. H., ... & Alberts, D. S. (2007). A meta-analysis of the efficacy of intraperitoneal sisplatin for the front-line treatment of ovarian cancer. International Journal of Gynecologic Cancer, 17(3).
Hilkens, P. H., van der Burg, M. E., Moll, J. W., Planting, A. S., van Putten, W. L., Vecht, C. J., & van den Bent, M. J. (1995). Neurotoxicity is not enhanced by increased dose intensities of sisplatin administration. Eur J Cancer, 31a(5), 678-681. doi:10.1016/0959-8049(94)00497-s
Hu, S., Leblanc, A. F., Gibson, A. A., Hong, K. W., Kim, J. Y., Janke, L. J., ... & Sparreboom, A. (2017). Identification of OAT1/OAT3 as contributors to sisplatin toxicity. Clinical and translational science, 10(5), 412-420.
Jamieson, E. R., & Lippard, S. J. (1999). Structure, recognition, and processing of sisplatin− DNA adducts. Chemical reviews, 99(9), 2467-2498.
Jangra, A., Kwatra, M., Singh, T., Pant, R., Kushwah, P., Ahmed, S., ... & Lahkar, M. (2016a). Edaravone alleviates sisplatin-induced neurobehavioral deficits via modulation of oxidative stress and inflammatory mediators in the rat hippocampus. European Journal of Pharmacology, 791, 51-61.
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2015). Third row transition metals for the treatment of cancer. Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences, 373(2037), 20140185.
Jordan, P., & Carmo-Fonseca*, M. (2000). Molecular mechanisms involved in sisplatin cytotoxicity. Cellular and Molecular Life Sciences CMLS, 57, 1229-1235.
Jung, Y., & Lippard, S. J. (2007). Direct cellular responses to platinum-induced DNA damage. Chemical reviews, 107(5), 1387-1407.
Kandula, T., Farrar, M. A., Cohn, R. J., Mizrahi, D., Carey, K., Johnston, K., ... & Park, S. B. (2018). Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer: clinical, neurophysiological, functional, and patient-reported outcomes. JAMA neurology, 75(8), 980-988.
Karale, S., & Kamath, J. V. (2017). Effect of daidzein on sisplatin-induced hematotoxicity and hepatotoxicity in experimental rats. Indian journal of pharmacology, 49(1), 49.
Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. Nature Reviews Cancer, 7(8), 573-584.
Khadrawy, Y. A., El-Gizawy, M. M., Sorour, S. M., Sawie, H. G., & Hosny, E. N. (2019). Effect of curcumin nanoparticles on the sisplatin-induced neurotoxicity in rat. Drug and Chemical Toxicology, 42(2), 194-202.
Kidera, Y., Kawakami, H., Sakiyama, T., Okamoto, K., Tanaka, K., Takeda, M., ... & Nakagawa, K. (2014). Risk factors for sisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PloS one, 9(7), e101902.
Kottschade, L. A., Sloan, J. A., Mazurczak, M. A., Johnson, D. B., Murphy, B. P., Rowland, K. M., ... & Loprinzi, C. L. (2011). The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Supportive Care in Cancer, 19, 1769-1777.
Krarup-Hansen, A., Helweg-Larsen, S., Schmalbruch, H., Rørth, M., & Krarup, C. (2007). Neuronal involvement in sisplatin neuropathy: prospective clinical and neurophysiological studies. Brain, 130(4), 1076-1088.
Lange, M., Heutte, N., Rigal, O., Noal, S., Kurtz, J. E., Lévy, C., ... & Joly, F. (2016). Decline in cognitive function in older adults with early-stage breast cancer after adjuvant treatment. The Oncologist, 21(11), 1337-1348.
Leo, M., Schmitt, L. I., Jastrow, H., Thomale, J., Kleinschnitz, C., & Hagenacker, T. (2017). Sisplatin alters the function and expression of N-type voltage-gated calcium channels in the absence of morphological damage of sensory neurons. Molecular pain, 13, 1744806917746565.
Lin, P. C., Lee, M. Y., Wang, W. S., Yen, C. C., Chao, T. C., Hsiao, L. T., . . . Chiou, T. J. (2006). N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support Care Cancer, 14(5), 484-487. doi:10.1007/s00520- 006-0018-9
Links, M., & Lewis, C. (1999). Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs, 57(3), 293-308. doi:10.2165/00003495-199957030-00003
Lomeli, N., Di, K., Czerniawski, J., Guzowski, J. F., & Bota, D. A. (2017). Sisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats. Free Radical Biology and Medicine, 102, 274-286.
Ma, J., Huo, X., Jarpe, M. B., Kavelaars, A., & Heijnen, C. J. (2018). Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of sisplatin treatment. Acta neuropathologica communications, 6(1), 1-14.
McWhinney, S. R., Goldberg, R. M., & McLeod, H. L. (2009). Platinum neurotoxicity pharmacogenetics. Molecular cancer therapeutics, 8(1), 10-16.
Miller, A. A., Wang, X. F., Gu, L., Hoffman, P., Khatri, J., Dunphy, F., . . . Green, M. R. (2008). Phase II randomized study of dose-dense docetaxel and sisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol, 3(10), 1159-1165. doi:10.1097/JTO.0b013e318186fb0d
Ongnok, B., Chattipakorn, N., & Chattipakorn, S. C. (2020). Doxorubicin and sisplatin induced cognitive impairment: the possible mechanisms and interventions. Experimental Neurology, 324, 113118.
Pabla, N., & Dong, Z. (2008). Sisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney international, 73(9), 994-1007.
Pabla, N., Murphy, R. F., Liu, K., & Dong, Z. (2009). The copper transporter Ctr1 contributes to sisplatin uptake by renal tubular cells during sisplatin nephrotoxicity. American Journal of Physiology-Renal Physiology, 296(3), F505-F511.
Pace, A., Giannarelli, D., Galie, E., Savarese, A., Carpano, S., Della Giulia, M., ... & Cognetti, F. (2010). Vitamin E neuroprotection for sisplatin neuropathy: a randomized, placebo-controlled trial. Neurology, 74(9), 762-766.
Pai, V. B., & Nahata, M. C. (2000). Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug safety, 22, 263-302.
Parker, R. J., Gill, I., Tarone, R., Vionnet, J. A., Grunberg, S., Muggia, F. M., & Reed, E. (1991). Platinum—DNA damage in leukocyte DNA of patients receiving carboplatin and sisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis, 12(7), 1253-1258.
Pignon, J. P., Tribodet, H., Scagliotti, G. V., Douillard, J. Y., Shepherd, F. A., Stephens, R. J., ... & Le Chevalier, T. (2008). Lung adjuvant sisplatin evaluation: a pooled analysis by the LACE Collaborative Group. In Database of Abstracts of Reviews of Effects (DARE): Quality-Assessed Reviews [Internet]. Centre for Reviews and Dissemination (UK).
Pinto-Leite, R., Arantes-Rodrigues, R., Palmeira, C., Colaço, B., Lopes, C., Colaço, A., ... & Santos, L. (2013). Everolimus combined with sisplatin has a potential role in treatment of urothelial bladder cancer. Biomedicine & Pharmacotherapy, 67(2), 116-121.
Planting, A. S. T., Catimel, G., De Mulder, P. H. M., De Graeff, A., Höppener, F., Verweij, I., ... & Neck Cooperative Group. (1999). Randomized study of a short course of weekly sisplatin with or without amifostine in advanced head and neck cancer. Annals of Oncology, 10(6), 693-700.
Podratz, J. L., Knight, A. M., Ta, L. E., Staff, N. P., Gass, J. M., Genelin, K., ... & Windebank, A. J. (2011). Sisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiology of disease, 41(3), 661-668.
Rademaker-Lakhai, J. M., Crul, M., Zuur, L., Baas, P., Beijnen, J. H., Simis, Y. J., ... & Schellens, J. H. (2006). Relationship between sisplatin administration and the development of ototoxicity. Journal of clinical oncology, 24(6), 918-924.
Raghavendra, V., Tanga, F., & DeLeo, J. A. (2003). Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. Journal of Pharmacology and Experimental Therapeutics, 306(2), 624-630.
Rosenberg, B., Van Camp, L., & Krigas, T. (1965). Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 205(4972), 698-699.
Rzeski, W., Pruskil, S., Macke, A., Felderhoff‐Mueser, U., Reiher, A. K., Hoerster, F., ... & Ikonomidou, C. (2004). Anticancer agents are potent neurotoxins in vitro and in vivo. Annals of neurology, 56(3), 351-360.
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019). Advances in toxicological research of the anticancer drug sisplatin. Chemical research in toxicology, 32(8), 1469-1486.
Siddik, Z. H. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 22(47), 7265-7279.
Simó, M., Root, J. C., Vaquero, L., Ripollés, P., Jové, J., Ahles, T., ... & Rodríguez-Fornells, A. (2015). Cognitive and brain structural changes in a lung cancer population. Journal of Thoracic Oncology, 10(1), 38-45.
Smyth, J. F., Bowman, A., Perren, T., Wilkinson, P., Prescott, R. J., Quinn, K. J., & Tedeschi, M. (1997). Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with sisplatin: results of a double-blind, randomised trial. Annals of oncology, 8(6), 569-573.
Starobova, H., & Vetter, I. (2017). Pathophysiology of chemotherapy-induced peripheral neuropathy. Frontiers in molecular neuroscience, 10, 174.
Ta, L. E., Bieber, A. J., Carlton, S. M., Loprinzi, C. L., Low, P. A., & Windebank, A. J. (2010). Transient Receptor Potential Vanilloid 1 is essential for sisplatin-induced heat hyperalgesia in mice. Molecular pain, 6, 1744-8069.
Ta, L. E., Espeset, L., Podratz, J., & Windebank, A. J. (2006). Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum–DNA binding. Neurotoxicology, 27(6), 992-1002.
Tomaszewski A, Büsselberg D. Sisplatin modulates voltage gated channel currents of dorsal root ganglion neurons of rats. Neurotoxicology 28(1): 49-58.
Townsend, D. M., & Hanigan, M. H. (2002). Inhibition of γ-glutamyl transpeptidase or cysteineS-conjugate β-lyase activity blocks the nephrotoxicity of sisplatin in mice. Journal of Pharmacology and Experimental Therapeutics, 300(1), 142-148.
Urien, S., & Lokiec, F. (2004). Population pharmacokinetics of total and unbound plasma sisplatin in adult patients. British journal of clinical pharmacology, 57(6), 756-763.
van Gerven, J. M., Hovestadt, A., Moll, J. W., Rodenburg, C. J., Splinter, T. A., van Oosterom, A. T., . . . et al. (1994). The effects of an ACTH (4-9) analogue on development of sisplatin neuropathy in testicular cancer: a randomized trial. J Neurol, 241(7), 432-435. doi:10.1007/bf00900961
Zajączkowska, R., Kocot-Kępska, M., Leppert, W., Wrzosek, A., Mika, J., & Wordliczek, J. (2019). Mechanisms of chemotherapy-induced peripheral neuropathy. International journal of molecular sciences, 20(6), 1451.
Zaki, S. M., Mohamed, E. A., Motawie, A. G., & Fattah, S. A. (2018). N-acetylcysteine versus progesterone on the sisplatin-induced peripheral neurotoxicity. Folia morphologica, 77(2), 234-245.
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8(1): 59-73, 2008

Details

Primary Language

English

Subjects

Structural Biology

Journal Section

Review

Authors

Mehmet Erdem ^*
0000-0002-5314-5209
Türkiye

Mehmet Özaslan
0000-0001-9380-4902
Türkiye

Early Pub Date

January 10, 2025

Publication Date

January 13, 2025

Submission Date

November 8, 2024

Acceptance Date

January 3, 2025

Published in Issue

Year 2025 Volume: 6 Number: 1

DOI

https://doi.org/10.55549/zbs.1581366

IZ

https://izlik.org/JA64AG49DU

APA

Erdem, M., & Özaslan, M. (2025). Cisplatin in Chemotherapy. Zeugma Biological Science, 6(1), 14-36. https://doi.org/10.55549/zbs.1581366

AMA

1.Erdem M, Özaslan M. Cisplatin in Chemotherapy. zbs. 2025;6(1):14-36. doi:10.55549/zbs.1581366

Chicago

Erdem, Mehmet, and Mehmet Özaslan. 2025. “Cisplatin in Chemotherapy”. Zeugma Biological Science 6 (1): 14-36. https://doi.org/10.55549/zbs.1581366.

EndNote

Erdem M, Özaslan M (January 1, 2025) Cisplatin in Chemotherapy. Zeugma Biological Science 6 1 14–36.

IEEE

[1]M. Erdem and M. Özaslan, “Cisplatin in Chemotherapy”, zbs, vol. 6, no. 1, pp. 14–36, Jan. 2025, doi: 10.55549/zbs.1581366.

ISNAD

Erdem, Mehmet - Özaslan, Mehmet. “Cisplatin in Chemotherapy”. Zeugma Biological Science 6/1 (January 1, 2025): 14-36. https://doi.org/10.55549/zbs.1581366.

JAMA

1.Erdem M, Özaslan M. Cisplatin in Chemotherapy. zbs. 2025;6:14–36.

MLA

Erdem, Mehmet, and Mehmet Özaslan. “Cisplatin in Chemotherapy”. Zeugma Biological Science, vol. 6, no. 1, Jan. 2025, pp. 14-36, doi:10.55549/zbs.1581366.

Vancouver

1.Mehmet Erdem, Mehmet Özaslan. Cisplatin in Chemotherapy. zbs. 2025 Jan. 1;6(1):14-36. doi:10.55549/zbs.1581366

Abstract

Cisplatin in Chemotherapy

Abstract

Keywords

References

Details

Primary Language

Subjects

Journal Section

Authors

Early Pub Date

Publication Date

Submission Date

Acceptance Date

Published in Issue

DOI

IZ

Cite